Stephan Stilgenbauer, MD, discusses efficacy data for tacabrutideg from CaDAnCe-101 and how it will inform future CLL research.
Back
Exploring BTK Degraders in CLL/SLL Management
Stephan Stilgenbauer, MD, and colleagues shared data for the first-in-class BTK degrader tacabrutideg in relapsed/refractory CLL/SLL.
Exploring BTK Degraders in CLL/SLL Management
Episodes
All
All
The first-in-class BTK degrader tacabrutideg produced an ORR of 94.1% at the recommended phase 2 dose in relapsed/refractory CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Zipalertinib Plus Chemotherapy Improves PFS in First-Line EGFR Exon 20 Insertion+ NSCLC
4
The OncFive: Top Oncology Articles for the Week of 8/9
5